

**REMARKS**

The Examiner alleges there are 2 separate and distinct inventions as follows:

Group I, claims 1-19 and 31 -35 drawn to a composition comprising two fusion polypeptides, the first having a transduction domain fused to a heterologous polypeptide, the second having a transduction domain fused to a fusogenic polypeptide, and kits and articles of manufacture thereof and just a fusion polypeptide comprising a protein transduction domain and a fusogenic domain.

Group II, claims 20-30 drawn to a method of introducing a heterologous polypeptide in to a target cell by contacting the cell with a composition comprising two fusion polypeptides, the first having a transduction domain fused to a heterologous polypeptide, the second having a transduction domain fused to a fusogenic polypeptide

In response to the Restriction Requirement Applicants elect the invention of Group I, claims 1-19 and 31 - 35 drawn to a composition comprising two fusion polypeptides, the first having a transduction domain fused to a heterologous polypeptide, the second having a transduction domain fused to a fusogenic polypeptide, and kits and articles of manufacture thereof and just a fusion polypeptide comprising a protein transduction domain and a fusogenic domain. Applicants further elect the species of TAT protein as set forth in claims 2 and 32. Claims 1, 15-19 and 31 are generic to this elected species. In addition, Applicants elect the species SV40 large T antigen as set forth in claim 12. Claims 1, 4, 6, 11, and 15-19 are generic to this elected species. Finally, Applicants elect the species of peptide analogs of influenza virus hemagglutinin as set forth in claims 13 and 34, Claims 1, 15-19, and 31 are generic to this elected species.

This election is made without traverse. Applicants reserve the right to rejoin non-elected species upon an indication of allowable subject matter.

The Examiner is invited to call the undersigned at 858.509.7300 should any additional issue remain regarding this response.


The Commissioner is hereby authorized to charge any fee deficiency or credit any overpayment of fees to Deposit Account No. 02-4800.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY LLP

Date: December 7, 2006

By: \_\_\_\_\_

  
Joseph R. Baker, Jr.  
Registration No. 40,900

P.O. Box 1404  
Alexandria, VA 22313-1404  
Tel: (858) 509-7300